Treatment of Aplastic Anemia in Patients Aged Over 60 Years
Aplastic anaemia presenting in patients older than 60 requires careful clinical judgement. Comorbidity and treatment tolerability reshape the risk-benefit balance, making quality-of-life assessment a central part of management in this age group.
Clinical Scenario
Treatment of elderly patients (aged over 60) with aplastic anaemia is more complex than in younger patients. Comorbidities and the toxicity profile of intensive therapy must both be weighed, and quality of life is especially relevant to treatment decision-making in this population.
Treatment approach: Immunosuppressive therapy is the treatment of choice in this age group, with the specific regimen and sequencing guided by individual patient factors and tolerance. The complete structured protocol details which therapeutic options apply and under what conditions.
References
DOI: 10.1111/bjh.19236
Treatment of elderly patients (>60 years) with AA is more complex than in younger patients due to comorbidity and treatment toxicity, and assessment of quality of life is especially relevant.
IST is the treatment of choice.
View source ↗